ClinicalTrials.Veeva

Menu
M

Mid Atlantic Retina | Bethlehem, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

APL-2
Pegcetacoplan
Eplerenone
EYE201
Bromfenac
Aflibercept
CU06-1004
SAR446597
MK-8748
Tarcocimab

Parent organization

This site is a part of Mid Atlantic Retina

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 16 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Active, not recruiting
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.Substudies...

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Available standard (usual) treatments for NVAMD, s...

Enrolling
Choroidal Neovascularization
Age-Related Macular Degeneration
Drug: Tiespectus
Drug: Aflibercept

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatmen...

Enrolling
Geographic Atrophy
Drug: Sham Comparator
Drug: SAR446597

This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participan...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Biological: SAR402663
Drug: Diluent

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

Trial sponsors

A
4
Regeneron Pharmaceuticals logo
Sanofi logo
W
Bayer logo
C
C
E
Kodiak Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems